Total Number of People With Diabetes
|
100,650
|
100%
|
11,826
|
11.7%
|
88,824
|
88.3%
|
–
|
Subgroup of Existing Insulin Users During the Pre-period
|
79,053
|
78.5%
|
10,975
|
92.8%
|
68,078
|
76.6%
|
< 0.0001
|
Characteristics
|
Age (n, %)
| | | | | | |
< 0.0001
|
18–40
|
8068
|
8.0%
|
4843
|
41.0%
|
3225
|
3.6%
| |
41–60
|
32,960
|
32.7%
|
4713
|
39.9%
|
28,247
|
31.8%
| |
> 60
|
59,622
|
59.2%
|
2270
|
19.2%
|
57,352
|
64.6%
| |
Age (mean, SD)
|
62.18
|
14.24
|
45.26
|
16.27
|
64.43
|
12.30
|
< 0.0001
|
Gender (n, %)
| | | | | | |
0.0003
|
Male
|
51,983
|
51.6%
|
6290
|
53.2%
|
45,693
|
51.4%
| |
Female
|
48,651
|
48.3%
|
5532
|
46.8%
|
43,119
|
48.5%
| |
Missing
|
16
|
0.0%
|
4
|
0.0%
|
12
|
0.0%
| |
Business Line (n, %)
| | | | | | |
< 0.0001
|
Commercial
|
43,573
|
43.3%
|
9566
|
80.9%
|
34,007
|
38.3%
| |
Medicare advantage
|
57,077
|
56.7%
|
2260
|
19.1%
|
54,817
|
61.7%
| |
Household Income, in US Dollars
|
n (%)
|
100,196
|
99.5%
|
11,801
|
99.8%
|
88,395
|
99.5%
| |
Median, Q1 - Q3
|
$54,143
|
$43,184 - $69,606
|
$63,304
|
$49,195 - $81,547
|
$53,299
|
$42,675 - $68,059
|
< 0.0001
|
Medical Claims
|
Number of Medical Claims (median, Q1 - Q3)
|
7.00
|
4.00–15.00
|
5.00
|
3.00–10.00
|
8.00
|
4.00–15.00
|
< 0.0001
|
Proportion of Medical Claims 2,3 That are Diabetes Related (mean, SD)
|
0.54
|
0.31
|
0.60
|
0.33
|
0.52
|
0.30
|
< 0.0001
|
Number of HbA1c Tests
|
One or More Tests Performed (n, %)
|
60,668
|
60.3%
|
7137
|
60.4%
|
53,531
|
60.3%
|
0.86
|
Mean, SD
|
0.91
|
0.93
|
0.89
|
0.88
|
0.91
|
0.94
|
0.0007
|
Latest HbA1c Value
|
n (%)
|
31,410
|
31.2%
|
3417
|
28.9%
|
27,993
|
31.5%
| |
Mean, SD
|
8.84
|
1.94
|
8.38
|
1.64
|
8.89
|
1.96
|
< 0.0001
|
Insulin Administration and Diabetes Technology (n, %)
| | | | | | |
< 0.0001
|
CGM with pump
|
1974
|
2.0%
|
1734
|
14.7%
|
240
|
0.3%
| |
CGM with pen
|
800
|
0.8%
|
342
|
2.9%
|
458
|
0.5%
| |
CGM with vial
|
277
|
0.3%
|
200
|
1.7%
|
77
|
0.1%
| |
BGM with pump
|
2098
|
2.1%
|
1516
|
12.8%
|
582
|
0.7%
| |
BGM with pen
|
23,078
|
22.9%
|
2032
|
17.2%
|
21,046
|
23.7%
| |
BGM with vial
|
8380
|
8.3%
|
1078
|
9.1%
|
7302
|
8.2%
| |
No CGM or BGM/pump
|
2410
|
2.4%
|
1236
|
10.5%
|
1174
|
1.3%
| |
No CGM or BGM/pen
|
44,108
|
43.8%
|
2208
|
18.7%
|
41,900
|
47.2%
| |
No CGM or BGM/vial
|
17,525
|
17.4%
|
1480
|
12.5%
|
16,045
|
18.1%
| |
Type of Insulin (n, %)
| | | | | | |
< 0.0001
|
N
|
77,912
|
77.4%
|
10,524
|
89.0%
|
67,388
|
75.9%
| |
Basal only
|
31,917
|
41.0%
|
893
|
8.5%
|
31,024
|
46.0%
| |
Bolus only
|
8949
|
11.5%
|
4742
|
45.1%
|
4207
|
6.2%
| |
Both
|
37,046
|
47.5%
|
4889
|
46.5%
|
32,157
|
47.7%
| |
Months on Insulin (mean, SD)
|
3.99
|
3.48
|
4.81
|
3.26
|
3.89
|
3.49
|
< 0.0001
|
Clinical Characteristics
|
Number of Concordant Comorbidities (mean, SD)
|
4.20
|
2.57
|
0.87
|
1.17
|
4.64
|
2.38
|
< 0.0001
|
Number of Discordant Comorbidities (mean, SD)
|
1.07
|
1.11
|
1.83
|
1.62
|
0.97
|
0.98
|
< 0.0001
|
Charlson Comorbidity Index (CCI) (mean, SD)
|
1.86
|
1.60
|
1.40
|
1.21
|
1.92
|
1.63
|
< 0.0001
|
Diabetes Complication Severity Index (DCSI) (mean, SD)
|
1.07
|
1.47
|
0.58
|
1.09
|
1.13
|
1.50
|
< 0.0001
|